Could adding immunotherapy after surgery keep lung cancer away?
NCT ID NCT07149363
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study tests whether adding an immunotherapy drug (durvalumab) to standard chemotherapy after surgery for early-stage small cell lung cancer helps keep the cancer from coming back. About 65 adults who had their lung cancer completely removed will receive this combination. The goal is to see if this approach improves how long people live without their cancer returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Virginia Comprehensive Cancer Center
RECRUITINGCharlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.